NHS rollout of artificial pancreas narrows inequality in diabetes care

The rollout of a “life-changing” artificial pancreas on the NHS for people with type 1 diabetes has helped to narrow ethnic and socioeconomic inequality within access to treatment, according to figures for England and Wales.

Officially known as a hybrid closed-loop system, an artificial pancreas comprises three interconnected parts: a sensor worn on the body called a continuous glucose monitor; an algorithm either built into the pump or on a separate device such as a phone that calculates the precise dose of insulin needed; and an insulin pump that delivers the dose into the bloodstream.

For patients, the device removes much of the mental burden of managing blood sugar levels, especially around mealtimes and during the night. According to previous clinical trials, the device is more effective at managing diabetes than current diabetes technology, such as using continuous glucose monitors alone.

Previous rollouts of diabetes technology have had stark disparities in uptake regarding ethnicity and deprivation. Studies have shown that people from minority ethnic backgrounds in England are less likely to have access to continuous glucose monitors, while people from deprived backgrounds have been unable to have full use of this tech.

However, the first two years of the artificial pancreas rollout in England and Wales has been seen to reverse this trend, with only a 3% difference in uptake between people from the most and least deprived backgrounds, as well as those from minority ethnic backgrounds compared with white counterparts.

Naiha Shafiq, 27, from London, was fitted with an artificial pancreas three years ago. She said the device had been “life-changing” because she was previously in and out of hospital with diabetic ketoacidosis, a life-threatening complication, as a result of struggling to administer her insulin injections.

Read full story

Source: The Guardian, 19 May 2026